Sorafenib delays recurrence and metastasis after liver transplantation in a rat model of hepatocellular carcinoma with high expression of phosphorylated extracellular signal‐regulated kinase
Jun Yan, Changjun Tan, Fangming Gu, Jiahao Jiang, Min Xu, Xiuzhen Huang, Zhi Dai, Zheng Wang, Jia Fan, Jian Zhou – 13 February 2013 – Liver transplantation (LT) is one of the curative treatments for hepatocellular carcinoma (HCC). However, cancer recurrence and metastasis after LT are common in some HCC patients with high‐risk factors (even in those within the Milan criteria). It remains unclear whether adjuvant therapy with sorafenib inhibits HCC recurrence and metastasis after LT. Therefore, we performed orthotopic LT in an August Irish Copenhagen (ACI) rat model of HCC.